This report summarizes estimates of health impact and cost-effectiveness of breast cancer screening that were created to assess the relative value of most of the clinical preventive services recommended by the United States Preventive Services Task Force (USPSTF) and the Advisory Committee on Immunization Practices (ACIP) for the general population. This ranking of clinical prevention priorities is guided by the National Commission on Prevention Priorities (NCPP).

USPSTF Recommendation: The U.S. Preventive Services Task Force (USPSTF) recommends biennial screening mammography for all women aged 50 to 74 years of age (B grade), and recommends that screening between ages 40 to 49 be left to individuals based upon their personal valuation of benefits and harms of screening (including false positives, unnecessary biopsies and overdiagnosis) and family history (C grade). In addition the USPSTF concluded that the current evidence is insufficient to assess the additional benefits and harms of screening mammography in women 75 years and older (I grade).The estimates in this report may not reflect current USPSTF recommendations. Readers are advised to check for updated recommendations at https://uspreventiveservicestaskforce.org.